200 related articles for article (PubMed ID: 32273474)
1. TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma.
Teramachi J; Tenshin H; Hiasa M; Oda A; Bat-Erdene A; Harada T; Nakamura S; Ashtar M; Shimizu S; Iwasa M; Sogabe K; Oura M; Fujii S; Kagawa K; Miki H; Endo I; Haneji T; Matsumoto T; Abe M
Haematologica; 2021 May; 106(5):1401-1413. PubMed ID: 32273474
[TBL] [Abstract][Full Text] [Related]
2. Myeloma-Bone Interaction: A Vicious Cycle via TAK1-PIM2 Signaling.
Harada T; Hiasa M; Teramachi J; Abe M
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503251
[TBL] [Abstract][Full Text] [Related]
3. The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells.
Tsubaki M; Seki S; Takeda T; Chihara A; Arai Y; Morii Y; Imano M; Satou T; Shimomura K; Nishida S
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114380
[TBL] [Abstract][Full Text] [Related]
4. Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation.
Xu G; Liu K; Anderson J; Patrene K; Lentzsch S; Roodman GD; Ouyang H
Blood; 2012 May; 119(18):4205-14. PubMed ID: 22427205
[TBL] [Abstract][Full Text] [Related]
5. TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis.
Lamothe B; Lai Y; Xie M; Schneider MD; Darnay BG
Mol Cell Biol; 2013 Feb; 33(3):582-95. PubMed ID: 23166301
[TBL] [Abstract][Full Text] [Related]
6. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL.
Huang H; Ryu J; Ha J; Chang EJ; Kim HJ; Kim HM; Kitamura T; Lee ZH; Kim HH
Cell Death Differ; 2006 Nov; 13(11):1879-91. PubMed ID: 16498455
[TBL] [Abstract][Full Text] [Related]
7. Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo.
Ai LS; Sun CY; Wang YD; Zhang L; Chu ZB; Qin Y; Gao F; Yan H; Guo T; Chen L; Yang D; Hu Y
Int J Cancer; 2013 Sep; 133(5):1074-84. PubMed ID: 23420490
[TBL] [Abstract][Full Text] [Related]
8. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
9. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6.
Mizukami J; Takaesu G; Akatsuka H; Sakurai H; Ninomiya-Tsuji J; Matsumoto K; Sakurai N
Mol Cell Biol; 2002 Feb; 22(4):992-1000. PubMed ID: 11809792
[TBL] [Abstract][Full Text] [Related]
10. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways.
Wei ZF; Tong B; Xia YF; Lu Q; Chou GX; Wang ZT; Dai Y
PLoS One; 2013; 8(3):e59171. PubMed ID: 23536866
[TBL] [Abstract][Full Text] [Related]
11. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
12. The scaffold protein RACK1 mediates the RANKL-dependent activation of p38 MAPK in osteoclast precursors.
Lin J; Lee D; Choi Y; Lee SY
Sci Signal; 2015 Jun; 8(379):ra54. PubMed ID: 26038599
[TBL] [Abstract][Full Text] [Related]
13. Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway.
Reuter S; Prasad S; Phromnoi K; Kannappan R; Yadav VR; Aggarwal BB
Mol Cancer Res; 2010 Oct; 8(10):1425-36. PubMed ID: 20826545
[TBL] [Abstract][Full Text] [Related]
14. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation.
Ichikawa H; Aggarwal BB
Clin Cancer Res; 2006 Jan; 12(2):662-8. PubMed ID: 16428513
[TBL] [Abstract][Full Text] [Related]
15. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction.
Kim K; Kim JH; Youn BU; Jin HM; Kim N
J Immunol; 2010 Dec; 185(12):7460-6. PubMed ID: 21068407
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.
Liu Z; Xu J; Li H; Zheng Y; He J; Liu H; Zhong Y; Lu Y; Hong B; Zhang M; Lin P; Du J; Hou J; Qian J; Kwak LW; Yi Q; Yang J
PLoS One; 2013; 8(12):e82453. PubMed ID: 24340030
[TBL] [Abstract][Full Text] [Related]
17. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
18. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhai ZJ; Li HW; Liu GW; Qu XH; Tian B; Yan W; Lin Z; Tang TT; Qin A; Dai KR
Br J Pharmacol; 2014 Feb; 171(3):663-75. PubMed ID: 24125472
[TBL] [Abstract][Full Text] [Related]
19. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
[TBL] [Abstract][Full Text] [Related]
20. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways.
Tsubaki M; Kato C; Manno M; Ogaki M; Satou T; Itoh T; Kusunoki T; Tanimori Y; Fujiwara K; Matsuoka H; Nishida S
Mol Cell Biochem; 2007 Oct; 304(1-2):53-60. PubMed ID: 17549607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
